Search | IOVS | ARVO Journals

Showing 1 – 20 of 20

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

Destructive neuroinflammation triggered by activation of the NLRP3 inflammasome in the glaucomatous optic nerve head

Meredith S Gregory-Ksander; Fei Fei; anitha krishnan; Te-Chen Tzeng; Deepa Subramanian; Douglas Golenbock; Ann Marshak-Rothstein; Bruce Ksander

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2021. doi: https://doi.org/

ARVO Annual Meeting Abstract September 2016

Soluble Fas ligand provides long-term protection in a chronic mouse model of glaucoma by inhibiting glial activation, inflammation, and apoptosis

Meredith S Gregory-Ksander; Fei Fei; Ann Marshak-Rothstein; Bruce Ksander; Anitha Krishnan

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi: https://doi.org/

ARVO Annual Meeting Abstract June 2015

Preventing glaucoma by blocking activation of the NLRP3 inflammasome in the optic nerve head

Fei Fei; Anitha Krishnan; Ann Marshak Rothstein; Bruce R Ksander; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3485. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2015

Vascular normalization: A novel method for inhibiting vascular leakage in age-related macular degeneration

Adarsha Koirala; Ann Marshak Rothstein; Bruce R Ksander; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4800. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2015

Gene therapy treatment with AAV-soluble Fas ligand protects retinal ganglion cells during development of Glaucoma

Anitha Krishnan; Fei Fei; Alexander Jones; Bruce R Ksander; Ann Marshak Rothstein; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2594. doi: https://doi.org/

ARVO Annual Meeting Abstract April 2014

Regulation of vascular leakage by Fas Ligand: Distinguishing the role of soluble from membrane FasL in unique knock-in mice with laser-induced choroidal neovascularization

Adarsha Koirala; Ann Marshak-Rothstein; Bruce R Ksander; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):80. doi: https://doi.org/

ARVO Annual Meeting Abstract April 2014

Soluble Fas ligand is a neuroprotective molecule critical in restricting glaucomatous damage to retinal ganglion cells

Anitha Krishnan; Alexander Jones; Ann Marshak Rothstein; Bruce R Ksander; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):2194. doi: https://doi.org/

ARVO Annual Meeting Abstract April 2011

Cleavage of Fas Ligand Regulates Vessel Leakage in Laser Induced CNV

Carolin Milojcic; Dimosthenis Mantopoulos; Demetrios Vavvas; Andrea Giani; Ann Marshak-Rothstein; Frank G. Holz; Bruce R. Ksander; Meredith S. Gregory

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):2300. doi: https://doi.org/

ARVO Annual Meeting Abstract April 2011

Accelerated Glaucoma And Increased Neurotoxicity In DBA/2J Mice That Cannot Cleave Fas Ligand

Bruce R. Ksander; Alexander Jones; Simon W. John; Ann Marshak-Rothstein; Meredith S. Gregory

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):2449. doi: https://doi.org/

ARVO Annual Meeting Abstract April 2010

Microglia Are Neurotoxic or Neuroprotective During the Development of Glaucoma Depending Upon the Expression of Membrane and Soluble FasL

M. S. Gregory; C. G. Hackett; E. Abernathy; A. Jones; M. R. Crane; A. Marshak-Rothstein; K. Lee; H. Chen; D. Chen; B. R. Ksander

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):3190. doi: https://doi.org/

ARVO Annual Meeting Abstract April 2009

The Form of Fas Ligand Determines Whether Retinal Ganglion Cells Survive or Die During Glaucoma

B. R. Ksander; C. G. Hackett; E. F. Abernathy; A. Marshak-Rothstein; K. Lee; D. F. Chen; M. S. Gregory

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):5925. doi: https://doi.org/

ARVO Annual Meeting Abstract April 2009

Both Membrane And Soluble Fas Ligand Are Required For Clearance Of Bacteria And Protection Of Host Tissue During S. aureus Induced Endophthalmitis.

C. G. Hackett; A. Marshak-Rothstein; M. S. Gregory

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):851. doi: https://doi.org/

ARVO Annual Meeting Abstract May 2007

Age-Related Spontaneous Corneal Lesions That Are Found Predominantly in Female CD36KO Mice

R. N. Barcia; S. Masli; K. Lee; A. Marshak-Rothstein; J. Zieske; M. Gregory-Ksander; B. R. Ksander

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):4324. doi: https://doi.org/

Immunology and Microbiology July 2005

A Novel Treatment for Ocular Tumors Using Membrane FasL Vesicles to Activate Innate Immunity and Terminate Immune Privilege

PDF

Meredith S. Gregory; Sean Koh; Eric Huang; Rebecca R. Saff; Ann Marshak-Rothstein; Shizuo Mukai; Bruce R. Ksander
TAGS: eye neoplasms, immunity, natural, tissue membrane, vaccination, neoplasms, tumor cells, vesicle, tumor necrosis factor ligand superfamily member 6
Invest. Ophthalmol. Vis. Sci.. 2005; 46(7):2495-2502. doi: https://doi.org/10.1167/iovs.05-0048

ARVO Annual Meeting Abstract May 2005

Soluble FasL Is Critical in Triggering Protective Anti–Bacterial Inflammation in the Eye

M.S. Gregory; M. Engelbert; M.S. Gilmore; A. Marshak–Rothstein; B.R. Ksander

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1171. doi: https://doi.org/

ARVO Annual Meeting Abstract May 2004

Intratumor injection of membrane Fas Ligand vesicles triggers innate immunity

E. Huang; M. Gregory; S. Koh; A. Marshak–Rothstein; S. Mukai; B.R. Ksander

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):593. doi: https://doi.org/

ARVO Annual Meeting Abstract May 2004

The eye possesses a unique immune privileged environment that contains high levels of modified soluble Fas ligand

M.S. Gregory; A.M. Hohlbaum; A. Marshak–Rothstein; B.R. Ksander

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):4520. doi: https://doi.org/

ARVO Annual Meeting Abstract May 2003

Expression of Soluble Fas Ligand in the Cornea Inhibits Lipopolysaccharide Induced Keratitis

V.L. Perez; M. Gregory; A. Marshak-Rothstein; B. Ksander

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):698. doi: https://doi.org/

ARVO Annual Meeting Abstract May 2003

A Novel Treatment for Ocular Tumors that Terminates Immune Privilege and Activates Innate Immunity

S. Koh; M.S. Gregory; A. Marshak-Rothstein; S. Mukai; B.R. Ksander

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):928. doi: https://doi.org/

ARVO Annual Meeting Abstract December 2002

Immune Privilege Sites Require a Higher Threshold Level of Membrane Fas Ligand to Stimulate Inflammation and Tumor Rejection

MS Gregory; A Repp; A Hohlbaum; R Saff; A Marshak-Rothstein; B Ksander

Invest. Ophthalmol. Vis. Sci.. 2002; 43(13):1952. doi: https://doi.org/

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Destructive neuroinflammation triggered by activation of the NLRP3 inflammasome in the glaucomatous optic nerve head

Soluble Fas ligand provides long-term protection in a chronic mouse model of glaucoma by inhibiting glial activation, inflammation, and apoptosis

Preventing glaucoma by blocking activation of the NLRP3 inflammasome in the optic nerve head

Vascular normalization: A novel method for inhibiting vascular leakage in age-related macular degeneration

Gene therapy treatment with AAV-soluble Fas ligand protects retinal ganglion cells during development of Glaucoma

Regulation of vascular leakage by Fas Ligand: Distinguishing the role of soluble from membrane FasL in unique knock-in mice with laser-induced choroidal neovascularization

Soluble Fas ligand is a neuroprotective molecule critical in restricting glaucomatous damage to retinal ganglion cells

Cleavage of Fas Ligand Regulates Vessel Leakage in Laser Induced CNV

Accelerated Glaucoma And Increased Neurotoxicity In DBA/2J Mice That Cannot Cleave Fas Ligand

Microglia Are Neurotoxic or Neuroprotective During the Development of Glaucoma Depending Upon the Expression of Membrane and Soluble FasL

The Form of Fas Ligand Determines Whether Retinal Ganglion Cells Survive or Die During Glaucoma

Both Membrane And Soluble Fas Ligand Are Required For Clearance Of Bacteria And Protection Of Host Tissue During S. aureus Induced Endophthalmitis.

Age-Related Spontaneous Corneal Lesions That Are Found Predominantly in Female CD36KO Mice

A Novel Treatment for Ocular Tumors Using Membrane FasL Vesicles to Activate Innate Immunity and Terminate Immune Privilege

Soluble FasL Is Critical in Triggering Protective Anti–Bacterial Inflammation in the Eye

Intratumor injection of membrane Fas Ligand vesicles triggers innate immunity

The eye possesses a unique immune privileged environment that contains high levels of modified soluble Fas ligand

Expression of Soluble Fas Ligand in the Cornea Inhibits Lipopolysaccharide Induced Keratitis

A Novel Treatment for Ocular Tumors that Terminates Immune Privilege and Activates Innate Immunity

Immune Privilege Sites Require a Higher Threshold Level of Membrane Fas Ligand to Stimulate Inflammation and Tumor Rejection

To View More...

You must be signed into an individual account to use this feature.